一分钟看懂
这是一项关于乳腺癌的III 期研究，登记的药物或干预包括Ribociclib；Letrozole；Ansastrozole；Goserelin；Leuprolide；Exemestane，当前状态为招募中。登记地点显示中国北京、广州、哈尔滨、郑州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Ribociclib；Letrozole；Ansastrozole；Goserelin；Leuprolide；Exemestane · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Novartis Investigative Site · 北京
- Novartis Investigative Site · 广州
- Novartis Investigative Site · 哈尔滨
- Novartis Investigative Site · 郑州
- Novartis Investigative Site · 南京
- Novartis Investigative Site · 南昌
- Novartis Investigative Site · 长春
- Novartis Investigative Site · 济南
- Novartis Investigative Site · 济宁
- Novartis Investigative Site · 成都
- Novartis Investigative Site · 乌鲁木齐
- Novartis Investigative Site · 杭州
- Novartis Investigative Site · 温州
- Novartis Investigative Site · 北京
- Novartis Investigative Site · 广州
- Novartis Investigative Site · 青岛
- Novartis Investigative Site · 上海
- Novartis Investigative Site · 石家庄
- Novartis Investigative Site · 天津
公开的入选条件
- Key Inclusion criteria:
- * Participant is an adult, male or female ≥ 18 years of age at the time of informed consent form signature (IC).
- * Participant has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer (BC) based on the most recently analyzed tissue sample tested by a local laboratory prior to enrollmen
- * Participant has HER2- BC defined as a negative in situ hybridization test or an immunohistochemistry (IHC) status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (FISH, CISH, or SISH) test is required by local laboratory testing based on the m
- * Participants may have already received any standard neoadjuvant and/or adjuvant ET, including tamoxifen or toremifene at the time of informed consent signature, but enrollment should occur within 36 months of prior ET start date and participants should have
- * For participants with prior ET treatment \> 12 months, restaging is highly recommended (unless contradictory to local regulations) to rule out disease recurrence prior to enrollment.
- * The number of participants with prior ET between 12 and 36 months will be capped at 30%. The cap will not apply to Black or African American participants.
- * Participant has no contraindication to receive adjuvant ET in the study.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05827081；登记信息更新于 2026-09-17。